MiNK Therapeutics Reports $2.74 Million Net Loss in Q1 2026, Advances Clinical Programs

MiNK Therapeutics, Inc. reported a net loss of $2.74 million for the first quarter of 2026, a slight improvement from a net loss of $2.77 million during the same period in 2025. The company’s operating loss increased to $2.88 million, compared to $2.70 million in the prior year, primarily due to a 32% rise in general and administrative expenses, which reached $1.68 million. This increase was attributed to higher share-based compensation and professional fees. Research and development expenses decreased by 5% to $1.20 million, reflecting reduced costs associated with clinical trials and a decrease in personnel costs.

As of March 31, 2026, MiNK's total assets were reported at $10.38 million, down from $14.24 million at the end of 2025. The decline in total assets was largely due to a decrease in cash and cash equivalents, which fell to $9.53 million from $13.36 million. The company’s accumulated deficit also increased to $159.42 million, up from $156.68 million at the end of the previous fiscal year. MiNK's total current liabilities decreased significantly to $7.29 million from $13.03 million, primarily due to the repayment of a related party note of $5 million in January 2026.

In terms of strategic developments, MiNK Therapeutics has been advancing its clinical programs, particularly its lead product candidate, agenT-797, which is currently in trials for solid tumors and critical pulmonary immune failure. The company has treated nearly 100 patients with agenT-797, generating insights that support its continued development. Additionally, MiNK has initiated a randomized Phase 2 trial for agenT-797 in patients with severe pneumonia and acute respiratory failure, with preliminary data expected in the latter half of 2026.

Operationally, MiNK's employee headcount has decreased, contributing to lower research and development costs. The company continues to explore additional funding sources, including strategic partnerships and collaborations, to support its liquidity needs. As of the end of the first quarter, MiNK had sold approximately 193,000 shares under its At Market Issuance Sales Agreement, generating net proceeds of about $3 million. The company believes that its current cash position, along with anticipated funding, will be sufficient to meet its liquidity requirements for more than a year, although it acknowledges substantial doubt about its ability to continue as a going concern.

Looking ahead, MiNK Therapeutics is focused on expanding its pipeline of engineered iNKT cell therapies and advancing its clinical trials. The company is optimistic about the potential of its proprietary technologies and the therapeutic applications of its iNKT cell platform in treating various cancers and immune-mediated diseases. However, the company cautions that achieving regulatory approval and market acceptance for its product candidates remains uncertain and will require significant additional expenditures.